Sfe Investment Counsel buys $5,070,495 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Sfe Investment Counsel scooped up 13,905 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 112,803 shares of Abbott Laboratories which is valued at $5,070,495.Abbott Laboratories makes up approximately 2.27% of Sfe Investment Counsel’s portfolio.

Other Hedge Funds, Including , Spectrum Management Group sold out all of its stake in ABT during the most recent quarter. The investment firm sold 1,050 shares of ABT which is valued $46,988. Sabal Trust Co added ABT to its portfolio by purchasing 9,122 company shares during the most recent quarter which is valued at $408,210. Abbott Laboratories makes up approx 0.05% of Sabal Trust Co’s portfolio.Retirement Systems Of Alabama boosted its stake in ABT in the latest quarter, The investment management firm added 664,950 additional shares and now holds a total of 1,417,189 shares of Abbott Laboratories which is valued at $61,888,644. Abbott Laboratories makes up approx 0.35% of Retirement Systems Of Alabama’s portfolio.Delta Asset Managementtn boosted its stake in ABT in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 3,695 shares of Abbott Laboratories which is valued at $159,513. Abbott Laboratories makes up approx 0.03% of Delta Asset Managementtn’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.53% at $45.02 with 76,57,947 shares getting traded on Monday. Post opening the session at $45.06, the shares hit an intraday low of $44.88 and an intraday high of $45.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *